We performed overnight polysomnography in 77 patients for diagnosis of sleep apnea syndrome (SAS) and assessment of severity. Patients were classified into 3 groups according to apnea index (AI): group 1 (G1; no SAS), AI < 10 (21 patients), group 2 (G2; moderate SAS), 10 < AI < 40 (34 patients), and group 3 (G3; severe SAS), AI ≧ 40 (22 patients). In all 3 groups, 60% of the apneas were obstructive, but the proportion of mixed apnea increased from G1 to G3 (6% in G1, 12% in G2, and 24% in G3). The duration of REM sleep was shorter in G2 and G3 than in G1 (G1 61 min, G2 44 min, G3 41 min; p < 0.03). In G3 a dramatic decrease in deep sleep was noted in comparison with G1 and G2 (G1 29 min, G2 31 min, G3 10 min). The distribution of the apnea in the different sleep stages was similar in G3; in G2, 16 patients had a REM apnea predominance, but in this subgroup duration of REM sleep was longer and AI was lower than in the other 18 G2 patients. So, absence of sleep stage apnea predominance and high proportion of mixed apnea were observed in the most severe SAS.

Keywords:
Sleep apnea syndrome, REM sleep, Polysomnography recordings, Mixed apnea, Severity criteria
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.